Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint

Contineum Therapeutics, Inc.

Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.
No significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms.
PIPE-307 demonstrated acceptable safety and tolerability at both doses.
Company will continue to analyze exploratory endpoints and plans future medical meeting presentation.
CEO and CMO express disappointment; focus remains on inflammatory and fibrotic disease pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.